<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975737</url>
  </required_header>
  <id_info>
    <org_study_id>02-GamTBvac-2020</org_study_id>
    <nct_id>NCT04975737</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac</brief_title>
  <official_title>Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac in Preventing the Development of Primary Respiratory Tuberculosis Not Associated With HIV Infection in Healthy Volunteers Aged 18-45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized (in 1:1 ratio) placebo-controlled study to&#xD;
      assess the safety and protective efficacy of the subunit recombinant tuberculosis vaccine&#xD;
      GamTBvac against the development of primary respiratory tuberculosis not associated with HIV&#xD;
      infection in healthy volunteers aged 18-45 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preventive efficacy (Ep)</measure>
    <time_frame>24 months after vaccination</time_frame>
    <description>Preventive efficacy calculated as Ep=(1-RR)âˆ—100%, where RR is the relative risk of developing pulmonary tuberculosis in the vaccine group compared to placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7180</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3590 healthy volunteers who will receive 1 dose (0.5 ml) of the vaccine GamTBvac administered twice with an 8-week interval between administrations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3590 healthy volunteers who will receive 1 dose (0.5 ml) of the placebo administered subcutaneously twice with an 8-week interval between administrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GamTBvac</intervention_name>
    <description>The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)</description>
    <arm_group_label>Vaccine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for subcutaneous administration</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female volunteers aged 18-45 years (inclusive);&#xD;
&#xD;
          2. Volunteers from population groups with a high incidence of tuberculosis (more than 30&#xD;
             people per 100 thousand population);&#xD;
&#xD;
          3. Absence of active tuberculosis, confirmed by chest x-ray;&#xD;
&#xD;
          4. Body mass index 18.5 - 30 kg / m2 (inclusive) according to Quetelet's weight and&#xD;
             height index;&#xD;
&#xD;
          5. Signed informed consent to participate in the study in accordance with the current&#xD;
             legislation;&#xD;
&#xD;
          6. Previous bacille Calmette Guerin (BCG) vaccination according to medical history or&#xD;
             confirmed by the presence of a scar;&#xD;
&#xD;
          7. Absence of markers of the immune response to mycobacterial proteins ESAT6 and CFP10,&#xD;
             which characterize the probable contact with M. tuberculosis prior to the start of the&#xD;
             study confirmed by the tuberculosis skin test;&#xD;
&#xD;
          8. Negative pregnancy test in female volunteers with preserved reproductive potential at&#xD;
             screening and on the day of the first vaccination;&#xD;
&#xD;
          9. Consent of male and female participants with preserved reproductive potential to&#xD;
             observe an adequate method of contraception (double barrier method: male or female&#xD;
             condom and combined hormonal contraceptive (oral, vaginal and transdermal forms can be&#xD;
             used) during the entire period of vaccination and 1 month after completion of&#xD;
             vaccination Exception: surgically sterile (more than 6 months) or postmenopausal (more&#xD;
             than 12 months);&#xD;
&#xD;
         10. Consent of male participants not to participate in sperm donation during the entire&#xD;
             period of vaccination and 1 month after completion of vaccination.&#xD;
&#xD;
        Non-inclusion criteria:&#xD;
&#xD;
          1. Positive test results for HIV-1/2 antibodies, HBsAg or hepatitis C antibodies at&#xD;
             screening;&#xD;
&#xD;
          2. History of tuberculosis (any localization);&#xD;
&#xD;
          3. History of chronic respiratory disease, including idiopathic pulmonary fibrosis (IPF),&#xD;
             bronchial asthma, chronic obstructive pulmonary disease (COPD), or pulmonary&#xD;
             hypertension.&#xD;
&#xD;
          4. Clinically significant ECG abnormalities at screening;&#xD;
&#xD;
          5. Aggravated allergic history;&#xD;
&#xD;
          6. Hypersensitivity to any component of the study drug or placebo; a history of drug&#xD;
             intolerance;&#xD;
&#xD;
          7. History or presence of any disease or drug intake that, in the opinion of the&#xD;
             investigator, may interfere with the assessment of the safety or efficacy of the&#xD;
             vaccine.&#xD;
&#xD;
          8. History or presence of any possible immunodeficiency state according to physical and&#xD;
             laboratory examination;&#xD;
&#xD;
          9. History of autoimmune disease (including systemic lupus erythematosus, type 1&#xD;
             diabetes, etc.);&#xD;
&#xD;
         10. Regular intake (lasting more than 2 weeks) of immunosuppressants or other&#xD;
             immunomodulatory drugs less than 6 months before the start of the study (except the&#xD;
             inhaled or topical forms of corticosteroids);&#xD;
&#xD;
         11. The use of immunoglobulin or blood products within 3 months before the start of the&#xD;
             study or their planned appointment during the study;&#xD;
&#xD;
         12. Intake of antibacterial drugs within 14 days before vaccination (oral) and within 28&#xD;
             days before vaccination (parenteral);&#xD;
&#xD;
         13. Pregnancy, lactation, refusal to use barrier methods of contraception, woman's&#xD;
             participation in an egg donation program;&#xD;
&#xD;
         14. Inability of the volunteer to understand the objectives, goals, research design,&#xD;
             inability to comply with the prescribed protocol and schedule of visits and&#xD;
             procedures;&#xD;
&#xD;
         15. Participation in clinical trials of medicinal products less than 3 months before the&#xD;
             start of this study, or planned participation in another clinical trial;&#xD;
&#xD;
         16. Previous receipt of the GamTBvac vaccine and / or participation in clinical trials of&#xD;
             any experimental anti-tuberculosis vaccines;&#xD;
&#xD;
         17. Any vaccination or planned vaccination less than a month before the first vaccination&#xD;
             in this study or within a month after each vaccination in this study.&#xD;
&#xD;
         18. Anamnestic information about alcoholism, drug addiction, drug abuse;&#xD;
&#xD;
         19. Positive result of urine analysis for narcotic and psychotropic drugs;&#xD;
&#xD;
         20. Positive test for ethanol (exhaled air).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participation of a volunteer in the study may be terminated for the following reasons:&#xD;
&#xD;
          1. Development of primary tuberculosis of the respiratory system;&#xD;
&#xD;
          2. The researcher decided that the volunteer should be excluded in the interests of the&#xD;
             volunteer himself;&#xD;
&#xD;
          3. The volunteer has a serious adverse event related to the study vaccine;&#xD;
&#xD;
          4. Failure to comply with the rules of participation in the study;&#xD;
&#xD;
          5. The participant refuses to cooperate or is undisciplined;&#xD;
&#xD;
          6. The participant was included in violation of the inclusion / non-inclusion criteria of&#xD;
             the protocol;&#xD;
&#xD;
          7. Development of any other significant adverse events;&#xD;
&#xD;
          8. Deterioration of the volunteer's health.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Semashko</last_name>
    <phone>+7 (499) 193-30-01</phone>
    <email>info@gamaleya.org</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

